Ophthalmology

The investigators use mindfulness-based cognitive therapy (MBCT) on patients who have never previously practiced the technique, with the aim of possibly re-training their brains to remove their static-type images.

Michael Rivers, MD, Senior Director of Ophthalmology at ModMed spoke with Modern Retina about their new single-screen initiative and the benefits it could have for saving time and simplifying communication within practices.

The recall is “due to potential safety concerns after FDA investigators found insanitary conditions.”

At first glance, these patients can appear to have normal or near-normal visual acuity levels. However, in reality, many have perceptual visual deficits, which are not typically tested during a standard ophthalmology office evaluation.

This is just one of many times the FDA has issued a warning to companies for the sale of unapproved ophthalmic products in 2023.

Mark Blecher, MD, spoke with the Ophthalmology Times team about his poster addressing retinal visualization and patients who've had small aperture IOL implantation at this year's American Academy of Ophthalmology meeting.

Penny Asbell, MD, FACS, spoke with Ophthalmology Times about her poster on results from the ARMOR Study and latest diagnostic and therapeutic advancements in ocular infections at this year's American Academy of Ophthalmology meeting.

Researchers found reduced iron concentration in the clear gel part of the eye of human patients and iron accumulation in the retina of mice.

A mutation-agnostic optogenetic gene therapy is in development using multi-characteristic opsin (MCO) to sensitize the retinal bipolar cells to detect light.

Oliver Hvidt, CEO and co-founder of Norlase, spoke with Ophthalmology Times about the company's 4-year journey from AAO 2019 to present at this year's American Academy of Ophthalmology meeting.

Nonetheless,BDUMP remains a rare condition with fewer than 60 cases documented in literature.

Sean Hanlon, CEO of CoFi, spoke with Ophthalmology Times about company updates as well as their integration with CareCredit at this year's American Academy of Ophthalmology meeting.

Rich Small, CEO of Neurotech, spoke with Ophthalmology Times about the company's development of encapsulated cell therapy, NT-501, at this year's American Academy of Ophthalmology meeting.

NYU Langone Health performs landmark procedure called “major paradigm shift for potential vision therapies”

Paul Runge, MD, FACS, spoke with Ophthalmology Times about his time in Ukraine treating retinopathy of prematurity (ROP) and implementing the Norlase Lion laser at this year's American Academy of Ophthalmology meeting.

A new study focuses on the specific visual field conditions and defects that can result in an increased risk of vehicular accidents, particularly in the aging population.

Researchers found that spontaneous macular hole closure and surgical treatment seem to be associated with comparable rates of closure and visual outcomes.

OCT and OCTA imaging were especially valuable in this patient population because the images extended the current definition of sickle cell retinopathy.

Researchers underscored the importance of ocular examinations in patients with primary vasculitis, defined as without an apparent cause.

Identifying and surmounting gender barriers in ophthalmology.

In July 2023, Harrow received certain US and Canadian commercial rights for 6 branded products from Santen.

Several companies including, Kiora Pharmaceuticals, Adverum Biotechnologies, and Aviceda Therapeutics, will share data at the meeting. Our team from Ophthalmology Times will also be in attendance.

The researchers pointed out the eye can be a challenge to sample in living patients as, much like the brain, it is non-regenerative and obtaining a tissue biopsy would cause irreparable damage.

Eclipsing 100,000 doses sold to retinal specialists within the first full year after commercial launch is an important milestone for the company.

In the wake of the October 7 surprise attack by Hamas, Israel finds itself thrust into war, and ophthalmologists are working to provide the best care they can under the conditions they find themselves in.

The patent covers the company’s development of this cell transplant therapy as a treatment for geographic atrophy.

Michael Engelbert, MD, PhD, discusses how personalized faricimab dosing shows promise in extending dosing intervals for patients with wet age-related macular degeneration, which can enhance long-term treatment outcomes and patient adherence.

Comments for the draft should be submitted by December 13, 2023.

The meeting, being held from October 11-14 in New York City, will feature 4 presentations from ophthalmologists of the New York Eye and Ear Infirmary of Mount Sinai.

According to Roche, faricimab (Vabysmo)showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studies.